Pliant Therapeutics, Inc.:
Focused on developing novel therapies for treatment of fibrosis. Pliant has developed a portfolio of fully-owned development candidates focused on inhibiting the TGFb pathway through integrin inhibition. The company’s lead product candidate, PLN-74809 is an oral small-molecule dual selective inhibitor of αvß6 and αvß1 integrins that is being developed in idiopathic pulmonary fibrosis (IPF), and primary sclerosing cholangitis (PSC). Positive results of a Phase 1b clinical study of PLN-7480 showed to inhibit TGF-β activation by up to 70% in alveolar macrophages collected from healthy volunteers, in a dose- and exposure-dependent manner. The second program, PLN-1474, targets advanced/end-stage liver fibrosis, and is in IND enabling studies. Pliant has a strategic licensing and collaboration agreement with Novartis covering the development and commercialization of our preclinical liver fibrosis program, PLN-1474 and up to three additional early stage integrin targets. Under the terms of the collaboration we will receive an up-front payment of $80 million, including $50 million of free cash and $30 million in equity investment commitments.
US - Pacific
Rare Disease, Respiratory
260 Littlefield Avenue
South San Francisco
South San Francisco, CA 94080
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Top 10 Holders of Pliant Therapeutics, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by